Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Astroglial correlates of neuropsychiatric disease: From astrocytopathy to astrogliosis.

Kim R, Healey KL, Sepulveda-Orengo MT, Reissner KJ.

Prog Neuropsychopharmacol Biol Psychiatry. 2017 Oct 6. pii: S0278-5846(17)30485-2. doi: 10.1016/j.pnpbp.2017.10.002. [Epub ahead of print] Review.

PMID:
28989099
2.

Menstrual Cycle in Schizophrenic Patients: Review with a Case.

Sönmez İ, Köşger F.

Noro Psikiyatr Ars. 2015 Dec;52(4):417-419. doi: 10.5152/npa.2015.7660. Epub 2015 Dec 1.

3.

Association Between Age at Onset of Schizophrenia and Age at Menarche.

Kiliçaslan EE, Erol A, Zengin B, Çetinay Aydin P, Mete L.

Noro Psikiyatr Ars. 2014 Sep;51(3):211-215. doi: 10.4274/npa.y6675. Epub 2014 Sep 1.

4.

Predictors of current functioning and functional decline in schizophrenia.

Joseph J, Kremen WS, Franz CE, Glatt SJ, van de Leemput J, Chandler SD, Tsuang MT, Twamley EW.

Schizophr Res. 2017 Oct;188:158-164. doi: 10.1016/j.schres.2017.01.038. Epub 2017 Jan 28.

PMID:
28139356
5.

Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review.

Gillespie AL, Samanaite R, Mill J, Egerton A, MacCabe JH.

BMC Psychiatry. 2017 Jan 13;17(1):12. doi: 10.1186/s12888-016-1177-y. Review.

6.

Patients with poor response to antipsychotics have a more severe pattern of frontal atrophy: a voxel-based morphometry study of treatment resistance in schizophrenia.

Quarantelli M, Palladino O, Prinster A, Schiavone V, Carotenuto B, Brunetti A, Marsili A, Casiello M, Muscettola G, Salvatore M, de Bartolomeis A.

Biomed Res Int. 2014;2014:325052. doi: 10.1155/2014/325052. Epub 2014 Jul 23.

7.
8.

A computed tomographic study of schizophrenia.

Siddharatha, Lal N, Tewari SC, Dalal PK, Kohli N, Srivastava S.

Indian J Psychiatry. 1997 Apr;39(2):115-21.

9.

A genome-wide study of common SNPs and CNVs in cognitive performance in the CANTAB.

Need AC, Attix DK, McEvoy JM, Cirulli ET, Linney KL, Hunt P, Ge D, Heinzen EL, Maia JM, Shianna KV, Weale ME, Cherkas LF, Clement G, Spector TD, Gibson G, Goldstein DB.

Hum Mol Genet. 2009 Dec 1;18(23):4650-61. doi: 10.1093/hmg/ddp413. Epub 2009 Sep 4.

10.
11.

Very poor outcome schizophrenia: clinical and neuroimaging aspects.

Mitelman SA, Buchsbaum MS.

Int Rev Psychiatry. 2007 Aug;19(4):345-57. Review.

12.

Genetics of schizophrenia: from animal models to clinical studies.

Joober R, Boksa P, Benkelfat C, Rouleau G.

J Psychiatry Neurosci. 2002 Sep;27(5):336-47. Review.

13.

T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variability.

Joober R, Benkelfat C, Brisebois K, Toulouse A, Turecki G, Lal S, Bloom D, Labelle A, Lalonde P, Fortin D, Alda M, Palmour R, Rouleau GA.

J Psychiatry Neurosci. 1999 Mar;24(2):141-6.

14.

Neuroleptics and psychic indifference: a review.

Healy D.

J R Soc Med. 1989 Oct;82(10):615-9. Review. No abstract available.

15.

Negative symptoms: psychopathological models.

Ananth J, Djenderdjian A, Shamasunder P, Costa J, Herrera J, Sramek J.

J Psychiatry Neurosci. 1991 Mar;16(1):12-8. Review.

16.

The relationship of structural brain imaging parameters to antipsychotic treatment response: a review.

Friedman L, Lys C, Schulz SC.

J Psychiatry Neurosci. 1992 Jun;17(2):42-54. Erratum in: J Psychiatry Neurosci 1992 Nov;17(5):205.

Supplemental Content

Support Center